A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease.

Translated title of the contribution: A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease.

W. Reinisch, D.W. Hommes, G. van Assche, J.F. Colombel, J.P. Gendre, B. Oldenburg, A. Teml, K. Geboes, H. Ding, L. Zhang, M. Tang, M. Cheng, S.J.H. van Deventer, P. Rutgeerts, T. Pearce

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionA dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease.
Original languageUndefined/Unknown
Pages (from-to)1138-1144
Number of pages7
JournalGut
Volume55
Publication statusPublished - 2006

Cite this